Try a new search

Format these results:

Searched for:

in-biosketch:yes

person:paganm02

Total Results:

256


How "rock-and-roll" solved the cullin supply chain problem

Garcia, Sheena Faye; Pagano, Michele
PMID: 37221268
ISSN: 1748-7838
CID: 5543712

A membrane-associated MHC-I inhibitory axis for cancer immune evasion

Chen, Xufeng; Lu, Qiao; Zhou, Hua; Liu, Jia; Nadorp, Bettina; Lasry, Audrey; Sun, Zhengxi; Lai, Baoling; Rona, Gergely; Zhang, Jiangyan; Cammer, Michael; Wang, Kun; Al-Santli, Wafa; Ciantra, Zoe; Guo, Qianjin; You, Jia; Sengupta, Debrup; Boukhris, Ahmad; Zhang, Hongbing; Liu, Cheng; Cresswell, Peter; Dahia, Patricia L M; Pagano, Michele; Aifantis, Iannis; Wang, Jun
Immune-checkpoint blockade has revolutionized cancer treatment, but some cancers, such as acute myeloid leukemia (AML), do not respond or develop resistance. A potential mode of resistance is immune evasion of T cell immunity involving aberrant major histocompatibility complex class I (MHC-I) antigen presentation (AP). To map such mechanisms of resistance, we identified key MHC-I regulators using specific peptide-MHC-I-guided CRISPR-Cas9 screens in AML. The top-ranked negative regulators were surface protein sushi domain containing 6 (SUSD6), transmembrane protein 127 (TMEM127), and the E3 ubiquitin ligase WWP2. SUSD6 is abundantly expressed in AML and multiple solid cancers, and its ablation enhanced MHC-I AP and reduced tumor growth in a CD8+ T cell-dependent manner. Mechanistically, SUSD6 forms a trimolecular complex with TMEM127 and MHC-I, which recruits WWP2 for MHC-I ubiquitination and lysosomal degradation. Together with the SUSD6/TMEM127/WWP2 gene signature, which negatively correlates with cancer survival, our findings define a membrane-associated MHC-I inhibitory axis as a potential therapeutic target for both leukemia and solid cancers.
PMID: 37557169
ISSN: 1097-4172
CID: 5602312

FBXL4 suppresses mitophagy by restricting the accumulation of NIX and BNIP3 mitophagy receptors

Nguyen-Dien, Giang Thanh; Kozul, Keri-Lyn; Cui, Yi; Townsend, Brendan; Kulkarni, Prajakta Gosavi; Ooi, Soo Siang; Marzio, Antonio; Carrodus, Nissa; Zuryn, Steven; Pagano, Michele; Parton, Robert G; Lazarou, Michael; Millard, S Sean; Taylor, Robert W; Collins, Brett M; Jones, Mathew Jk; Pagan, Julia K
To maintain both mitochondrial quality and quantity, cells selectively remove damaged or excessive mitochondria through mitophagy, which is a specialised form of autophagy. Mitophagy is induced in response to diverse conditions, including hypoxia, cellular differentiation and mitochondrial damage. However, the mechanisms that govern the removal of specific dysfunctional mitochondria under steady-state conditions to fine-tune mitochondrial content are not well understood. Here, we report that SCFFBXL4 , an SKP1/CUL1/F-box protein ubiquitin ligase complex, localises to the mitochondrial outer membrane in unstressed cells and mediates the constitutive ubiquitylation and degradation of the mitophagy receptors NIX and BNIP3 to suppress basal levels of mitophagy. We demonstrate that the pathogenic variants of FBXL4 that cause encephalopathic mtDNA depletion syndrome (MTDPS13) do not efficiently interact with the core SCF ubiquitin ligase machinery or mediate the degradation of NIX and BNIP3. Thus, we reveal a molecular mechanism whereby FBXL4 actively suppresses mitophagy by preventing NIX and BNIP3 accumulation. We propose that the dysregulation of NIX and BNIP3 turnover causes excessive basal mitophagy in FBXL4-associated mtDNA depletion syndrome.
PMID: 37161784
ISSN: 1460-2075
CID: 5538212

Apoptotic cell death in disease-Current understanding of the NCCD 2023

Vitale, Ilio; Pietrocola, Federico; Guilbaud, Emma; Aaronson, Stuart A; Abrams, John M; Adam, Dieter; Agostini, Massimiliano; Agostinis, Patrizia; Alnemri, Emad S; Altucci, Lucia; Amelio, Ivano; Andrews, David W; Aqeilan, Rami I; Arama, Eli; Baehrecke, Eric H; Balachandran, Siddharth; Bano, Daniele; Barlev, Nickolai A; Bartek, Jiri; Bazan, Nicolas G; Becker, Christoph; Bernassola, Francesca; Bertrand, Mathieu J M; Bianchi, Marco E; Blagosklonny, Mikhail V; Blander, J Magarian; Blandino, Giovanni; Blomgren, Klas; Borner, Christoph; Bortner, Carl D; Bove, Pierluigi; Boya, Patricia; Brenner, Catherine; Broz, Petr; Brunner, Thomas; Damgaard, Rune Busk; Calin, George A; Campanella, Michelangelo; Candi, Eleonora; Carbone, Michele; Carmona-Gutierrez, Didac; Cecconi, Francesco; Chan, Francis K-M; Chen, Guo-Qiang; Chen, Quan; Chen, Youhai H; Cheng, Emily H; Chipuk, Jerry E; Cidlowski, John A; Ciechanover, Aaron; Ciliberto, Gennaro; Conrad, Marcus; Cubillos-Ruiz, Juan R; Czabotar, Peter E; D'Angiolella, Vincenzo; Daugaard, Mads; Dawson, Ted M; Dawson, Valina L; De Maria, Ruggero; De Strooper, Bart; Debatin, Klaus-Michael; Deberardinis, Ralph J; Degterev, Alexei; Del Sal, Giannino; Deshmukh, Mohanish; Di Virgilio, Francesco; Diederich, Marc; Dixon, Scott J; Dynlacht, Brian D; El-Deiry, Wafik S; Elrod, John W; Engeland, Kurt; Fimia, Gian Maria; Galassi, Claudia; Ganini, Carlo; Garcia-Saez, Ana J; Garg, Abhishek D; Garrido, Carmen; Gavathiotis, Evripidis; Gerlic, Motti; Ghosh, Sourav; Green, Douglas R; Greene, Lloyd A; Gronemeyer, Hinrich; Häcker, Georg; Hajnóczky, György; Hardwick, J Marie; Haupt, Ygal; He, Sudan; Heery, David M; Hengartner, Michael O; Hetz, Claudio; Hildeman, David A; Ichijo, Hidenori; Inoue, Satoshi; Jäättelä, Marja; Janic, Ana; Joseph, Bertrand; Jost, Philipp J; Kanneganti, Thirumala-Devi; Karin, Michael; Kashkar, Hamid; Kaufmann, Thomas; Kelly, Gemma L; Kepp, Oliver; Kimchi, Adi; Kitsis, Richard N; Klionsky, Daniel J; Kluck, Ruth; Krysko, Dmitri V; Kulms, Dagmar; Kumar, Sharad; Lavandero, Sergio; Lavrik, Inna N; Lemasters, John J; Liccardi, Gianmaria; Linkermann, Andreas; Lipton, Stuart A; Lockshin, Richard A; López-Otín, Carlos; Luedde, Tom; MacFarlane, Marion; Madeo, Frank; Malorni, Walter; Manic, Gwenola; Mantovani, Roberto; Marchi, Saverio; Marine, Jean-Christophe; Martin, Seamus J; Martinou, Jean-Claude; Mastroberardino, Pier G; Medema, Jan Paul; Mehlen, Patrick; Meier, Pascal; Melino, Gerry; Melino, Sonia; Miao, Edward A; Moll, Ute M; Muñoz-Pinedo, Cristina; Murphy, Daniel J; Niklison-Chirou, Maria Victoria; Novelli, Flavia; Núñez, Gabriel; Oberst, Andrew; Ofengeim, Dimitry; Opferman, Joseph T; Oren, Moshe; Pagano, Michele; Panaretakis, Theocharis; Pasparakis, Manolis; Penninger, Josef M; Pentimalli, Francesca; Pereira, David M; Pervaiz, Shazib; Peter, Marcus E; Pinton, Paolo; Porta, Giovanni; Prehn, Jochen H M; Puthalakath, Hamsa; Rabinovich, Gabriel A; Rajalingam, Krishnaraj; Ravichandran, Kodi S; Rehm, Markus; Ricci, Jean-Ehrland; Rizzuto, Rosario; Robinson, Nirmal; Rodrigues, Cecilia M P; Rotblat, Barak; Rothlin, Carla V; Rubinsztein, David C; Rudel, Thomas; Rufini, Alessandro; Ryan, Kevin M; Sarosiek, Kristopher A; Sawa, Akira; Sayan, Emre; Schroder, Kate; Scorrano, Luca; Sesti, Federico; Shao, Feng; Shi, Yufang; Sica, Giuseppe S; Silke, John; Simon, Hans-Uwe; Sistigu, Antonella; Stephanou, Anastasis; Stockwell, Brent R; Strapazzon, Flavie; Strasser, Andreas; Sun, Liming; Sun, Erwei; Sun, Qiang; Szabadkai, Gyorgy; Tait, Stephen W G; Tang, Daolin; Tavernarakis, Nektarios; Troy, Carol M; Turk, Boris; Urbano, Nicoletta; Vandenabeele, Peter; Vanden Berghe, Tom; Vander Heiden, Matthew G; Vanderluit, Jacqueline L; Verkhratsky, Alexei; Villunger, Andreas; von Karstedt, Silvia; Voss, Anne K; Vousden, Karen H; Vucic, Domagoj; Vuri, Daniela; Wagner, Erwin F; Walczak, Henning; Wallach, David; Wang, Ruoning; Wang, Ying; Weber, Achim; Wood, Will; Yamazaki, Takahiro; Yang, Huang-Tian; Zakeri, Zahra; Zawacka-Pankau, Joanna E; Zhang, Lin; Zhang, Haibing; Zhivotovsky, Boris; Zhou, Wenzhao; Piacentini, Mauro; Kroemer, Guido; Galluzzi, Lorenzo
Apoptosis is a form of regulated cell death (RCD) that involves proteases of the caspase family. Pharmacological and genetic strategies that experimentally inhibit or delay apoptosis in mammalian systems have elucidated the key contribution of this process not only to (post-)embryonic development and adult tissue homeostasis, but also to the etiology of multiple human disorders. Consistent with this notion, while defects in the molecular machinery for apoptotic cell death impair organismal development and promote oncogenesis, the unwarranted activation of apoptosis promotes cell loss and tissue damage in the context of various neurological, cardiovascular, renal, hepatic, infectious, neoplastic and inflammatory conditions. Here, the Nomenclature Committee on Cell Death (NCCD) gathered to critically summarize an abundant pre-clinical literature mechanistically linking the core apoptotic apparatus to organismal homeostasis in the context of disease.
PMCID:10130819
PMID: 37100955
ISSN: 1476-5403
CID: 5465212

CDT1, a licensing factor that limits rereplication

Rona, Gergely; Pagano, Michele
Cells must avoid licensing of neosynthesized DNA to prevent rereplication. In this issue of Molecular Cell, Ratnayeke et al. (2022)1 reveal how the licensing factor CDT1, prior to its degradation, inhibits DNA elongation by suppressing CMG helicase progression at replication forks.
PMID: 36608666
ISSN: 1097-4164
CID: 5410172

Extracellular matrix stiffness regulates degradation of MST2 via SCF βTrCP

Fiore, Ana Paula Zen Petisco; Rodrigues, Ana Maria; Ribeiro-Filho, Helder Veras; Manucci, Antonio Carlos; de Freitas Ribeiro, Pedro; Botelho, Mayara Carolinne Silva; Vogel, Christine; Lopes-de-Oliveira, Paulo Sergio; Pagano, Michele; Bruni-Cardoso, Alexandre
The Hippo pathway plays central roles in relaying mechanical signals during development and tumorigenesis, but how the proteostasis of the Hippo kinase MST2 is regulated remains unknown. Here, we found that chemical inhibition of proteasomal proteolysis resulted in increased levels of MST2 in human breast epithelial cells. MST2 binds SCFβTrCP E3 ubiquitin ligase and silencing βTrCP resulted in MST2 accumulation. Site-directed mutagenesis combined with computational molecular dynamics studies revealed that βTrCP binds MST2 via a non-canonical degradation motif. Additionally, stiffer extracellular matrix, as well as hyperactivation of integrins resulted in enhanced MST2 degradation mediated by integrin-linked kinase (ILK) and actomyosin stress fibers. Our study uncovers the underlying biochemical mechanisms controlling MST2 degradation and underscores how alterations in the microenvironment rigidity regulate the proteostasis of a central Hippo pathway component.
PMID: 36044955
ISSN: 1872-8006
CID: 5332142

The NSP14/NSP10 RNA repair complex as a Pan-coronavirus therapeutic target

Rona, Gergely; Zeke, Andras; Miwatani-Minter, Bearach; de Vries, Maren; Kaur, Ramanjit; Schinlever, Austin; Garcia, Sheena Faye; Goldberg, Hailey V; Wang, Hui; Hinds, Thomas R; Bailly, Fabrice; Zheng, Ning; Cotelle, Philippe; Desmaële, Didier; Landau, Nathaniel R; Dittmann, Meike; Pagano, Michele
The risk of zoonotic coronavirus spillover into the human population, as highlighted by the SARS-CoV-2 pandemic, demands the development of pan-coronavirus antivirals. The efficacy of existing antiviral ribonucleoside/ribonucleotide analogs, such as remdesivir, is decreased by the viral proofreading exonuclease NSP14-NSP10 complex. Here, using a novel assay and in silico modeling and screening, we identified NSP14-NSP10 inhibitors that increase remdesivir's potency. A model compound, sofalcone, both inhibits the exonuclease activity of SARS-CoV-2, SARS-CoV, and MERS-CoV in vitro, and synergistically enhances the antiviral effect of remdesivir, suppressing the replication of SARS-CoV-2 and the related human coronavirus OC43. The validation of top hits from our primary screenings using cellular systems provides proof-of-concept for the NSP14 complex as a therapeutic target.
PMCID:8640510
PMID: 34862481
ISSN: 1476-5403
CID: 5069282

EMSY inhibits homologous recombination repair and the interferon response, promoting lung cancer immune evasion

Marzio, Antonio; Kurz, Emma; Sahni, Jennifer M; Di Feo, Giuseppe; Puccini, Joseph; Jiang, Shaowen; Hirsch, Carolina Alcantara; Arbini, Arnaldo A; Wu, Warren L; Pass, Harvey I; Bar-Sagi, Dafna; Papagiannakopoulos, Thales; Pagano, Michele
Non-small cell lung cancers (NSCLCs) harboring KEAP1 mutations are often resistant to immunotherapy. Here, we show that KEAP1 targets EMSY for ubiquitin-mediated degradation to regulate homologous recombination repair (HRR) and anti-tumor immunity. Loss of KEAP1 in NSCLC induces stabilization of EMSY, producing a BRCAness phenotype, i.e., HRR defects and sensitivity to PARP inhibitors. Defective HRR contributes to a high tumor mutational burden that, in turn, is expected to prompt an innate immune response. Notably, EMSY accumulation suppresses the type I interferon response and impairs innate immune signaling, fostering cancer immune evasion. Activation of the type I interferon response in the tumor microenvironment using a STING agonist results in the engagement of innate and adaptive immune signaling and impairs the growth of KEAP1-mutant tumors. Our results suggest that targeting PARP and STING pathways, individually or in combination, represents a therapeutic strategy in NSCLC patients harboring alterations in KEAP1.
PMID: 34963055
ISSN: 1097-4172
CID: 5108142

The Long-Lost Ligase: CRL4AMBRA1 Regulates the Stability of D-Type Cyclins

Chaikovsky, Andrea C; Sage, Julien; Pagano, Michele; Simoneschi, Daniele
D-type cyclins (cyclin D1, D2, and D3, together cyclin D) are central drivers of the cell division cycle and well-described proto-oncoproteins. Rapid turnover of cyclin D is critical for its regulation, but the underlying mechanism has remained a matter of debate. Recently, AMBRA1 was identified as the major regulator of the stability of all three D-type cyclins. AMBRA1 serves as the substrate receptor for one of ∼40 CUL4-RING E3 ubiquitin ligase (CRL4) complexes to mediate the polyubiquitylation and subsequent degradation of cyclin D. Consequently, AMBRA1 regulates cell proliferation to impact tumor growth and the cellular response to cell cycle-targeted cancer therapies. Here we discuss the findings that implicate AMBRA1 as a core member of the cell cycle machinery.
PMID: 34495753
ISSN: 1557-7430
CID: 5031122

A Novel FBXO45-Gef-H1 Axis Controls Oncogenic Signaling in B-Cell Lymphoma [Meeting Abstract]

Sahasrabuddhe, A A; Chen, X; Ma, K; Wu, R; Kapoor, R; Chhipa, R R; Zhang, X; Onder, O; Wilmore, J; Gaudette, B T; Pillai, V; Li, M M; Ahn, J -Y; Chung, F; Szankasi, P; Basrur, V; Conlon, K P; Bailey, N G; Hogaboam, C M; Rottapel, R; Kim, J; Lopez, C; Seufert, J; Schlesner, M; Siebert, R; Cancro, M P; Allman, D; Pagano, M; Staudt, L M; Lim, M S; Elenitoba-Johnson, K S J
Introduction: Diffuse large B cell lymphoma (DLBCL) is the most common form of malignant lymphoma and may arise de novo, or through transformation from a pre-existing low-grade B cell lymphoma such as follicular lymphoma (FL). However, the post-translational mechanisms and deregulated pathways underlying the pathogenesis of disease evolution are not fully understood.
Method(s): We employed integrated functional and structural genomics and mass spectrometry (MS)-driven proteomics which implicated a possible novel tumor suppressor role for a conserved E3 ubiquitin ligase FBXO45 in DLBCL pathogenesis. We generated conditional knockout mice targeting loss of Fbxo45 in germinal center (GC) B-cells using the Cg1-Cre-loxP system and an assortment of CRISPR-mediated knockouts of FBXO45 in B cell lymphoma cells (FL518, BJAB, U2932). We engineered B cell lines (BJAB, U2932) to inducibly express FLAG-tagged FBXO45 to identify candidate substrates of FBXO45 using liquid chromatography-tandem MS. In vitro biochemical and in vivo studies using a variety of genetically-modified lines in xenograft studies in immunodeficient mice were performed to validate observations from proteogenomic studies. Whole genome sequencing (WGS) and genomic copy number studies were interrogated to investigate structural alterations targeting FBXO45 in primary human lymphoma samples.
Result(s): Conditional targeting of Fbxo45 in GCB-cells in transgenic mice resulted in abnormal germinal center formation with increased number and size of germinal centers. Strikingly, targeted deletion of Fbxo45 in GCB-cells resulted in spontaneous B cell lymphomas with (22/22);100%) penetrance and none of the wild-type (WT) littermates (0/20; 0%) developed lymphoma at 24 months. Macroscopic examination revealed large tumor masses, splenomegaly, and lymphadenopathy at different anatomic locations including ileocecal junction, mesenteric, retroperitoneal and cervical lymph nodes and thymus. Next generation sequencing of immunoglobulin heavy chain genes revealed monoclonal or oligoclonal B cell populations. Using proteomic analysis of affinity-purified FBXO45-immunocomplexes and differential whole proteome analysis from GCB-cells of Fbxo45 wt/wt vs Fbxo45 fl/fl mice, we discovered that FBXO45 targets the RHO guanine exchange factor GEF-H1 for ubiquitin-mediated proteasomal degradation. FBXO45 exclusively interacts with GEF H1 among 8 F-box proteins investigated and silencing of FBXO45 using three independent shRNA and CRISPR-Cas9-mediated knockouts in B-cell lymphoma cell lines promotes RHOA and MAPK activation, B cell growth and enhances proliferation. GEF-H1 is stabilized by FBXO45 depletion and GEF-H1 ubiquitination by FBXO45 requires phosphorylation of GEF-H1. Importantly, FBXO45 depletion and expression of a GEF-H1 mutant that is unable to bind FBXO45 results in GEF-H1 stabilization, promotes hyperactivated RHO and MAPK signaling and B-cell oncogenicity in vitro and in vivo. Notably, this phenotype is reverted by co-silencing of GEF-H1. Inducible ectopic expression of FBXO45 triggers accelerated turnover of GEF H1 and decreased RHOA signaling. Genomic analyses revealed recurrent loss targeting FBXO45 in transformed DLBCL (25%), de novo DLBCL (6.6%) and FL (2.3%). In keeping with our observation of prolonged hyperactivation of pERK1/2 consequent to FBXO45 ablation, in vitro and in vivo studies using B-cell lymphoma cell lines and xenografts demonstrated increased sensitivity to pharmacologic blockade with the MAP2K1/2 (ERK1/2) inhibitor Trametinib.
Conclusion(s): Our findings define a novel FBXO45-GEF-H1-MAPK signalling axis, which plays an important role in DLBCL pathogenesis. Our studies carry implications for potential exploitation of this pathway for targeted therapies. Disclosures: Siebert: AstraZeneca: Speakers Bureau. Lim: EUSA Pharma: Honoraria.
Copyright
EMBASE:2016079441
ISSN: 0006-4971
CID: 5098732